posteditor

posteditor

GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting

B -DMD preclinical data support candidate declaration for GB703, a potential DMD gene therapy designed to broaden mutation coverage and improve muscle delivery -SMA1 preclinical data support the ongoing CHARISMA Phase 1/2 clinical trial for SMA1, which is advancing on…

Cellebrite Announces First-Quarter 2026 Results

B First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32% Q2 Outlook Highlights ARR Acceleration TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ — Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital…

WhiteFiber, Inc. Reports First Quarter 2026 Results

B NEW YORK, May 14, 2026 /PRNewswire/ — WhiteFiber, Inc. (Nasdaq: WYFI) (“WhiteFiber” or the “Company”), a leading provider of AI infrastructure and high-performance computing solutions, today announced financial results for the first quarter ended March 31, 2026. Sam Tabar,…